Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Chemical & Pharmaceutical Bulletin|February 18, 2026
Mirror-Image D-Core Streptavidin Exhibits Reduced Immunogenicity and Comparable Biodistribution to Natural Core Streptavidin in MiceMasatoshi Suganuma, Aya Sugyo, Hitomi Sudo, et al.
International Journal of Oncology|November 21, 2013
AHNAK is highly expressed and plays a key role in cell migration and invasion in mesotheliomaHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Cancer Science|October 25, 2011
ZDHHC8 knockdown enhances radiosensitivity and suppresses tumor growth in a mesothelioma mouse modelHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Cancers|December 9, 2020
Proof of Concept Study for Increasing Tenascin-C-Targeted Drug Delivery to Tumors Previously Subjected to Therapy: X-Irradiation Increases Tumor UptakeAya Sugyo, Atsushi B Tsuji, Hitomi Sudo, et al.
Cancer Reports (Hoboken, N.J.)|October 15, 2023
Wnt1 induces osteoblastic changes in a well-established osteolytic skeletal metastatic model derived from breast cancerAya Sugyo, Atsushi B Tsuji, Hitomi Sudo, et al.
Nuclear Medicine Communications|September 20, 2023
The tyrosine kinase inhibitor nintedanib enhances the efficacy of 90 Y-labeled B5209B radioimmunotherapy targeting ROBO1 without increased toxicity in small-cell lung cancer xenograft miceKentaro Fujiwara, Atsushi B Tsuji, Hitomi Sudo, et al.
Nuclear Medicine Communications|August 11, 2015
Preclinical evaluation of 2-amino-2-[11C]methyl-butanoic acid as a potential tumor-imaging agent in a mouse modelChie Suzuki, Atsushi B Tsuji, Koichi Kato, et al.
Biochemical and Biophysical Research Communications|October 30, 2007
A loss of function screen identifies nine new radiation susceptibility genesHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Nuclear Medicine Communications|January 22, 2026
Intrathoracic 90Y-NZ-16 therapy improves efficacy and reduces toxicity in pleural mesothelioma miceHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Cancer Science|February 26, 2019
Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesotheliomaHitomi Sudo, Atsushi B Tsuji, Aya Sugyo, et al.
Pageof 6